CN1519018A - Combination of medicine for treating hepatitis - Google Patents
Combination of medicine for treating hepatitis Download PDFInfo
- Publication number
- CN1519018A CN1519018A CNA031592163A CN03159216A CN1519018A CN 1519018 A CN1519018 A CN 1519018A CN A031592163 A CNA031592163 A CN A031592163A CN 03159216 A CN03159216 A CN 03159216A CN 1519018 A CN1519018 A CN 1519018A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- hepatitis
- radix
- medicine
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating hepatitides and hepatic disfunction caused by hepatitis and protecting liver is prepared from 8 Chinese-medicinal materials including giant knotweed rhizome, lysimachia, gymstemma pentaphyllum, astragalus root, etc.
Description
Technical field
The present invention relates to a kind of is the pharmaceutical composition of the treatment hepatitis made of raw material with the vegetable Chinese herbal medicine.
Technical background
China is the sick district occurred frequently of hepatitis, a tree name interrelated data report, and China's hepatitis virus (HBV) infection rate reaches 50～60%, HBV carrier more than 100,000,000 is arranged, ten thousand people surplus the hepatitis B patient 270 are arranged every year, and more than 80 ten thousand neonates are subjected to HBV and infect, and have considerable part to become the HBV lifelong carrier.Over nearly more than 20 years, obtained gratifying achievements in fields such as basic research and hepatitis preventions, first, hepatitis B vaccine comes into operation.But, in the radical cure viral hepatitis, particularly the chronic hepatitis aspect does not still have breakthrough, the treatment of chronic hepatitis is still the difficult problem that the clinician feels a delicacy about, still the ideal medicament that lacks the treatment chronic hepatitis so far, above situation proves absolutely viral hepatitis in the popular seriousness of the China and even the whole world, and therefore carrying out the research that prevents and treats the viral hepatitis medicine seems very urgent.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition that acute and chronic hepatitis is had therapeutic effect.
The pharmaceutical composition of treatment hepatitis of the present invention is the medicament of being made by the following weight proportion raw material: Radix Cudraniae 70-100g, Radix berchemiae lineatae 70-100g, Rhizoma Polygoni Cuspidati 30-50g, Herba Desmodii Styracifolii 70-100g, Cornu Bubali 70-100g, Herb Gynostemmae Pentaphylli 30-50g, Radix Astragali 30-50g, Carapax Et Plastrum Testudinis 7-10g.
In the pharmaceutical composition of the present invention with the Radix Cudraniae promoting blood circulation to restore menstrual flow, remove damp and hot, the jaundice eliminating subcutaneous ulcer, the Radix berchemiae lineatae eliminating stasis to stop pain is monarch drug altogether; Be aided with Rhizoma Polygoni Cuspidati invigorate blood circulation analgesic therapy, clearing away heat-damp and promoting diuresis, detoxifcation, Herba Desmodii Styracifolii dehumidifying jaundice eliminating, detoxifcation, the Cornu Bubali clearing away heat and cooling blood, detoxifcation, the Herb Gynostemmae Pentaphylli heat-clearing and toxic substances removing be ministerial drug altogether, with reinforcement monarch drug effect; Be equipped with the Carapax Et Plastrum Testudinis nourishing YIN for benefiting the kidney, in order to avoid impairment of YIN is an adjuvant drug; Be equipped with Radix Astragali tonifying Qi and lifting yang, invigorating spleen for diuresis again, " disease for the treatment of the liver, must tonifying the spleen " be adjuvant.All medicines share, and clearing away heat-damp and promoting diuresis, detoxifcation pain-relieving functions are arranged.Be used for jaundice due to damp-heat, hypochondriac pain, the liver function injury due to hepatoprotective and the acute, chronic hepatitis.
Pharmaceutical composition of the present invention is a peroral dosage form, and dose is adult's 40-80 gram on the one.
The pharmacological research of pharmaceutical composition of the present invention:
One, acute toxicity test
The mouse stomach administration, Cmax and maximum volume fail to measure LD
50, its maximum tolerated dose 270g (crude drug)/kg body weight is clinical plan daily dose (1.12g crude drug/kg/ day) 241 times.Each Mus outward appearance behavior behind the medicine, appetite is drained not unusual, body weight gain.
Two, long term toxicity test
Rat is raised this pharmaceutical composition of clothes and is equivalent to crude drug 56g, 33.6g, 11.2g/kg/ day (for 50,30,10 times of daily doses of clinical plan) once a day, continuous 180 days.As a result, each treated animal is at duration of test, and movable normal, behavior is active.The hair smoothness, do not see that feces is unusual, none death, hematology, blood biochemical are learned and are checked, the small dose group total white blood cells is lower than matched group when removing detection in 90 days, but still in the biological value scope, female rats AST, ALT all are higher than matched group during detection in 180 days, but still in the biological value scope, the every index of all the other each treated animals there is no unusually.Important vital organ perusals such as the heart, liver, spleen, lung, kidney and histopathologic examination be no abnormality seen also.
Three, pharmacodynamics test
This pharmaceutical composition has protective effect to rat acute hepatic injury due to the D-Gal, can reduce glutamate pyruvate transaminase, suppresses the minimizing of glycogen content.Immunity test can obviously improve the phagocytic percentage and the phagocytic index of Turnover of Mouse Peritoneal Macrophages, to due to the counter inhibitor hydroprednisone acetate (prednisolone) the decline of serum lyase, antibody formation effect is strengthened, obviously improve immunologic function.The test of the anti-HBV in inside and outside, HBsAg and inhibition duck liver virus: in the anti-hepatitis virus test: no matter vivo and vitro all has obvious inhibitory action to HBsAg, HBeAg, DHBVDNA, DHBeAg to this pharmaceutical composition, Cavia porcellus is produced anti-HBs obvious facilitation, has certain immunity.
1, rat acute hepatic injury due to the D-Gal there is protective effect
The result shows that the effect that this pharmaceutical composition high dose level all had inhibition ALT value to rise on the 3rd day relatively has significant difference (P＜0.05) with the D-Gal group after the D-Gal administration.And increase with dosage and to act on reinforcement, tangible dose-effect relationship is arranged.
2, to Immune Effects
(1) to the influence of Turnover of Mouse Peritoneal Macrophages phagocytic function
The result shows: three dosage groups of this pharmaceutical composition have the effect that improves the Turnover of Mouse Peritoneal Macrophages phagocytic function, compare with levamisole, and the nonspecific immunity potentiation of this pharmaceutical composition is a little more than the former.In this pharmaceutical composition, low dose of strong to the bigger dosage of the potentiation of Turnover of Mouse Peritoneal Macrophages phagocytic function.
(2) to the influence of mice serum lysozyme
The result shows that three dosage groups of this pharmaceutical composition can be resisted the decline of the serum lysozyme due to the immunosuppressant, with the andrographolide group significant difference (P＜0.05) is arranged relatively.
(3) antagonist forms the influence of cell (IgM-PFC)
The result shows that mice is significantly increased mouse spleen relative weight and humoral immune function through drinking this pharmaceutical composition diluent after 2 weeks in suitable 4.5g/kg dosage group.13.5g/kg the dosage group has certain potentiation to humoral immune function.
(4) to the influence of delayed allergy
The result shows that mice is drunk this pharmaceutical composition diluent after 2 weeks, and each dosage group there is no the pair cell immunologic function tangible influence (P＞0.05).
3, the test of the anti-HBV in inside and outside, HBsAg and inhibition duck liver virus
(1) effect of application 2,2, the 15 anti-HBV of cells in vitro
The result shows, wears three dosage groups of golden the liver benefiting sheet, after the dosing 2-10 days to the suppression ratio of HBsAg at 31.7-47.8%, show slight inhibition; At 12-14 days, suppression ratio was at 52.4-61.5%, and showing has obvious inhibitory action, and this inhibitory action increases with drug level and the test period prolongation is strengthened.
(2) effect of vitro inhibition HBsAg
The result shows, this pharmaceutical composition 0.25g/ml, 0.50g/ml, 1.0g/ml are diluted to 1: 6 respectively, 1: 32, HBsAg are all had inhibitory action at 1: 64 o'clock, YIGANNING 1.0g/ml is diluted at 1: 64 o'clock has inhibitory action to HBsAg, the then unrestraint effect of Polyporus negative control medicine.
(3) Cavia porcellus is produced the regulating action of anti--HBs
The result shows that each group of this pharmaceutical composition all is higher than blank group (P＜0.05) since the 2nd blood sampling averaging of income P/N value.This pharmaceutical composition 1g/ml and 0.5g/ml group mean P/N value are similar to the polyporusum bellatus group, 0.25g/ml is then a little less than the polyporusum bellatus group, illustrate that this pharmaceutical composition produces anti--HBs to Cavia porcellus and obvious facilitation arranged, have certain immunity, and its immunity strengthens with dosage.
(4) to the inhibitory action of DHV
The result shows that the dirty histopathological examination of each group experiment duck liver is most normal, and the liver inflammation changes most not obvious.
Four, clinical research result
1, treatment group obvious effective rate, effective percentage are respectively 34.5%, 54%, and total effective rate is 88.5%; Matched group obvious effective rate, effective percentage are respectively 26%, 58%, and total effective rate is 84%.
2, the clinical symptoms efficacy result shows, symptoms such as jaundice, hypochondriac pain, poor appetite, vomiting and nausea, abdominal distention, heavy sensation of the body, asthenia all have clear improvement after the patient.
The specific embodiment
Get raw material by following weight proportion: Radix Cudraniae 82g, Radix berchemiae lineatae 82g, Rhizoma Polygoni Cuspidati 41g, Herba Desmodii Styracifolii 82g, Cornu Bubali 82g, Herb Gynostemmae Pentaphylli 41g, Radix Astragali 41g, Carapax Et Plastrum Testudinis 8g.
More than eight flavors, get Carapax Et Plastrum Testudinis and pulverize, cross sieve No. 1; Other Cornu Bovis seu Bubali pound flakiness of fetching water, Carapax Et Plastrum Testudinis powder and Cornu Bubali slice decoct with water three times, and each 5 hours, replenish the moisture that boils off in the decoction process at any time, collecting decoction filters, and filtrate is concentrated into relative 1.30 density～1.35 (80 ℃); Six-elements such as all the other Radix Cudraniaes, Radix berchemiae lineatae decoct with water three times, and each 2 hours, collecting decoction, filter, filtrate is concentrated into relative density 1.15～1.18 (80 ℃), and it is 70% that adding ethanol makes medicinal liquid contain the alcohol amount, leaves standstill 12 hours, the leaching supernatant reclaims ethanol, adds Carapax Et Plastrum Testudinis and Cornu Bubali concentrated solution, continues to concentrate, be dried to dry extract, be ground into fine powder, adding starch is an amount of, mixing is made granule, and compacting in flakes, sugar coating, aluminum-plastic packaged, promptly make 100 tablets of medicaments.
Claims (1)
1, a kind of pharmaceutical composition for the treatment of hepatitis is characterized in that it being the medicament of being made by the following weight proportion raw material: Radix Cudraniae 70-100g, Radix berchemiae lineatae 70-100g, Rhizoma Polygoni Cuspidati 30-50g, Herba Desmodii Styracifolii 70-100g, Cornu Bubali 70-100g, Herb Gynostemmae Pentaphylli 30-50g, Radix Astragali 30-50g, Carapax Et Plastrum Testudinis 7-10g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03159216 CN1233388C (en) | 2003-09-02 | 2003-09-02 | Combination of medicine for treating hepatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03159216 CN1233388C (en) | 2003-09-02 | 2003-09-02 | Combination of medicine for treating hepatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1519018A true CN1519018A (en) | 2004-08-11 |
| CN1233388C CN1233388C (en) | 2005-12-28 |
Family
ID=34287308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03159216 Expired - Fee Related CN1233388C (en) | 2003-09-02 | 2003-09-02 | Combination of medicine for treating hepatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1233388C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100444857C (en) * | 2006-07-06 | 2008-12-24 | 汪甬伟 | Medicine for auxiliary treating hepatitis |
| CN100448462C (en) * | 2006-07-06 | 2009-01-07 | 李强 | Synergistic medicinal composition containing diammonium glycyrrhizinate and Chinese medicine |
| CN101502572B (en) * | 2009-03-11 | 2010-10-13 | 张砚 | Auxiliary Chinese and western medicinal composition for treating hepatitis |
| CN101862380A (en) * | 2010-02-10 | 2010-10-20 | 李瑞菊 | Medicinal composition |
| CN103977365A (en) * | 2014-06-06 | 2014-08-13 | 马朝富 | Traditional Chinese medicine preparation for treating hypochondriac pain and preparation method thereof |
| CN105853525A (en) * | 2016-05-24 | 2016-08-17 | 广西邦琪药业集团有限公司 | Medicine composition for treating jaundice, hypochondriac pain and acute and chronic hepatitis |
-
2003
- 2003-09-02 CN CN 03159216 patent/CN1233388C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100444857C (en) * | 2006-07-06 | 2008-12-24 | 汪甬伟 | Medicine for auxiliary treating hepatitis |
| CN100448462C (en) * | 2006-07-06 | 2009-01-07 | 李强 | Synergistic medicinal composition containing diammonium glycyrrhizinate and Chinese medicine |
| CN101502572B (en) * | 2009-03-11 | 2010-10-13 | 张砚 | Auxiliary Chinese and western medicinal composition for treating hepatitis |
| CN101862380A (en) * | 2010-02-10 | 2010-10-20 | 李瑞菊 | Medicinal composition |
| CN103977365A (en) * | 2014-06-06 | 2014-08-13 | 马朝富 | Traditional Chinese medicine preparation for treating hypochondriac pain and preparation method thereof |
| CN105853525A (en) * | 2016-05-24 | 2016-08-17 | 广西邦琪药业集团有限公司 | Medicine composition for treating jaundice, hypochondriac pain and acute and chronic hepatitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1233388C (en) | 2005-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1593472A (en) | Pharmaceutical composition for treating liver diseases and its application | |
| CN1233388C (en) | Combination of medicine for treating hepatitis | |
| CN1977852B (en) | Medicinal composition containing stilbene total glycoside and its use for pharmaceutical treating hepatitis B | |
| CN1069542C (en) | Medicine for treating chronic hepatism and its preparing process | |
| CN101933973B (en) | Medicament composition for preventing and treating liver damage | |
| CN1056755C (en) | Medicine of curing hepatitis | |
| CN101186627B (en) | Method for preparing picroside I | |
| CN1234381C (en) | Medicine compositions for treating hepatitis, and its prepn. method | |
| CN1229124C (en) | Medicine for treating fatty liver | |
| CN1087617C (en) | Hepatitis curing capsule | |
| CN101574426B (en) | Chinese patent medicament for treating liver diseases and method for preparing same | |
| CN1899574A (en) | Chinese medicine composition for preventing and controlling liver cancer and its use | |
| CN1903276A (en) | Medicinal composition for treating hepatitis B | |
| CN100386087C (en) | Use of kutkin I in preparing drug for treating hepatitis B, its formulation and preparation method | |
| CN1111064C (en) | Hepatitis treating medicine and its production process | |
| CN1562184A (en) | Preparation of Chinese traditional medicine for curing female inflammation and preparation method | |
| CN103239569B (en) | Application of viola diffusa in preparation of medicine for treating viral hepatitis | |
| CN1086129C (en) | Hepatitis restoration pill | |
| CN1814250A (en) | Chinese medicine composition for treating liver cirrhosis ascites and use thereof | |
| CN1291729C (en) | Antiviral Chinese medicine prepn of Hypericum perforatumand its prepn process | |
| CN1676143A (en) | Chinese medicine compound formulation for treating rheumatism | |
| CN101700323B (en) | Pharmaceutical composition for preventing and treating liver cancer | |
| CN102068658B (en) | Chinese medicine composite for clearing heat, detoxicating, dispelling dampness and eliminating stagnation and preparation method thereof | |
| CN1634260A (en) | Novel method for preparing 'Bazheng Tablet' | |
| CN1242768C (en) | Hepatitis treating medicine and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051228 Termination date: 20100902 |